Table of Content

Open Access iconOpen Access

ARTICLE

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo

Leonard Lothstein*, Judith Soberman, Deanna Parke*, Jatin Gandhi*, Trevor Sweatman, Tiffany Seagroves*

* Department of Pathology and Laboratory Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA
† Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA
‡ Department of Pharmacology, The University of Tennessee Health Science Center, Memphis, TN, USA

Oncology Research 2020, 28(5), 451-465. https://doi.org/10.3727/096504020X15898794315356

Abstract

Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and circumvents resistance conferred by overexpression of P-glycoprotein, Bcl-2, Bcl-XL, and Bcr-Abl. As a consequence, pivarubicin is more cytotoxic than doxorubicin against MDA-MB-231, and SUM159 TNBC cell lines grown in both monolayer culture and tumorspheres. Comparative in vivo efficacy of pivarubicin and doxorubicin was performed in an orthotopic NSG mouse model implanted with MDA-MB-231 human TNBC cells and treated with the maximum tolerated doses (MTDs) of pivarubicin and doxorubicin. Tumor growth was monitored by digital caliper measurements and determination of endpoint tumor weight and volume. Endpoint cardiotoxicity was assessed histologically by identifying microvacuolization in ventricular cardiomyocytes. Primary tumors treated with multiple rounds of doxorubicin at MTD failed to inhibit tumor growth compared with vehicletreated tumors. However, administration of a single MTD of pivarubicin produced significant inhibition of tumor growth and tumor regression relative to tumor volume prior to initiation of treatment. Histological analysis of hearts excised from drug- and vehicle-treated mice revealed that pivarubicin produced no evidence of myocardial damage at a therapeutic dose. These results support the development of pivarubicin as a safer and more effective replacement for doxorubicin against TNBC as well as other malignancies for which doxorubicin therapy is indicated.

Keywords


Cite This Article

APA Style
Lothstein, L., Soberman, J., Parke, D., Gandhi, J., Sweatman, T. et al. (2020). Pivarubicin is more effective than doxorubicin against triple-negative breast cancer in vivo. Oncology Research, 28(5), 451-465. https://doi.org/10.3727/096504020X15898794315356
Vancouver Style
Lothstein L, Soberman J, Parke D, Gandhi J, Sweatman T, Seagroves T. Pivarubicin is more effective than doxorubicin against triple-negative breast cancer in vivo. Oncol Res. 2020;28(5):451-465 https://doi.org/10.3727/096504020X15898794315356
IEEE Style
L. Lothstein, J. Soberman, D. Parke, J. Gandhi, T. Sweatman, and T. Seagroves "Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo," Oncol. Res., vol. 28, no. 5, pp. 451-465. 2020. https://doi.org/10.3727/096504020X15898794315356



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 676

    View

  • 475

    Download

  • 0

    Like

Share Link